FIELD: medicine, experimental oncology and phthisiology.
SUBSTANCE: invention can be used for modeling combined pathology of lung carcinoma and tuberculosis. C57BL/6 mice are simultaneously inoculated into the lateral vein of the tail with a suspension of Mycobacterium tuberculosis strain at a dose of 106 microbial cells in 0.2 ml of saline and transplanted into the muscle of the right thigh of the animal with a 10% suspension in saline of Lewis epidermoid carcinoma of the lung in a volume of 0.2 ml. Then the development of pathology is controlled on the 14th and 21st day.
EFFECT: invention provides for the creation of an experimental highly reproducible model of the combined pathology of cancer and tuberculosis, which most accurately reflects the clinical course of each of the diseases.
3 cl, 14 dwg, 6 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
STRAIN MYCOBACTERIUM TUBERCULOSIS 326/18/47 B-9673 FOR EVALUATION OF THE EFFECTIVENESS OF ANTI-TB DRUGS AND DISINFECTANTS | 2022 |
|
RU2785409C1 |
ANTITUBERCULAR AGENT BASED ON A PYRIDOXINE DERIVATIVE | 2021 |
|
RU2772219C1 |
COFORMULATED ANTITUBERCULOUS DRUG | 2009 |
|
RU2430724C2 |
AGENT EXHIBITING BACTERIOSTATIC ACTIVITY ON MULTIRESISTANT MYCOBACTERIUM TUBERCULOSIS STRAINS IN EXPERIMENT | 2015 |
|
RU2602450C1 |
COMBINED ANTITUBERCULOUS COMPOSITION | 2009 |
|
RU2413517C1 |
IMMUNOTHERAPEUTIC AGENT FOR PRIMARY PREVENTION OF TUBERCULOSIS | 2009 |
|
RU2544125C2 |
COMPOSITIONS AND METHODS FOR TREATING ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION | 2013 |
|
RU2659149C2 |
ANTITUBERCULOUS VACCINE | 2007 |
|
RU2443773C2 |
DIMEPHOSPHONE ISONICOTINOYLHYDRAZONE WITH ANTI-TUBERCULOSIS ACTIVITY | 2011 |
|
RU2457212C1 |
DIMEPHOSPHONE NICOTINOYLHYDRAZONE POSSESSING ANTI-TUBERCULOSIS ACTIVITY | 2011 |
|
RU2471787C1 |
Authors
Dates
2023-08-01—Published
2022-12-08—Filed